Summary of the II International Symposium on Cytomegalovirus

Antiviral Research

Volumn 39, Issue 3, 1998, Pages 141-162

  De Jong, Menno D ^a   Galasso, George J ^b   Gazzard, Brian ^c   Griffiths, Paul D ^d   Jabs, Douglas A ^e   Kern, Earl R ^f   Spector, Stephen A ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g Div of Infect Dis Univ of C   (United States)

Author keywords

Diagnosis; Human cytomegalovirus; Prophylaxis; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTISENSE OLIGODEOXYNUCLEOTIDE; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; LOBUCAVIR;

BETAHERPESVIRINAE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CONGENITAL INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; DNA VIRUS; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LATENT VIRUS INFECTION; MONOCYTE; MONONUCLEOSIS; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SOCIOECONOMICS; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; TISSUE TRANSPLANTATION; VIRAL VACCINES;

BETAHERPESVIRINAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HERPESVIRIDAE; HUMAN HERPESVIRUS 5;

EID: 0032192290     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00044-8     Document Type: Review

References (127)

1. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., Best A.M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171:1995;26-32.
2. Alain S., Honderlick P., Grenet D., Stern M., Vadam C., Sanson-Le Pors M.J., Mazeron M.C. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation. 63:1997;1533-1536.
3. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., Azad R.F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40:1996;2004-2011.
4. Arevalo J.F., Gonzalez C., Capparelli E.V., Kirsch L.S., Garcia R.F., Quinceno J.I., Connor J.D., Gambertoglio J., Bergeron-Lynn G., Frederick W.R. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J. Infect. Dis. 172:1995;951-956.
5. Bachmann M.F., Kalinke U., Althage A., Freer G., Burkhart C., Roost H., Aguet M., Hengartner H., Zinkernagel R.M. The role of antibody concentration and avidity in antiviral protection. Science. 276:1997;2024-2027.
6. Badley A.D., Portela D.F., Patel R., Kyle R.A., Habermann T.M., Strickler J.G., Ilstrup D.M., Wiesner R.H., de Groen P., Walker R.C., Paya C.V. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl. Surg. 2:1996;375-382.
7. Badley A.D., Seaberg E.C., Porayko M.K., Wiesner R.H., Keating M.R., Wilhelm M.P., Walker R.C., Patel R., Marshall W.F., DeBernardi M., Zetterman R., Steers J.L., Paya C.V. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation. 64:1997;66-73.
8. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., Silini F., Gerna G. Single amino acid changes in the DNA polymerse confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 170:1996;1390-1395.
9. Balfour H.H.J., Chace B.A., Stapleton J.T., Simmons R.L., Fryd D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320:1989;1381-1387.
10. Barbi M., Binda S., Primache V., Novelli C. Cytomegalovirus in peripheral blood leukocytes of infants with congenital or postnatal infection. Pediatr. Infect. Dis. J. 15:1996;898-903.
11. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 88:1996;4063-4071.
12. Boesch C., Issakainen J., Kewitz G., Kikinis R., Martin E., Boltshauser E. Magnetic resonance imaging of the brain in congenital cytomegalovirus infection. Pediatr. Radiol. 19:1989;91-93.
13. Boivin G., Chou S., Quirk M.R., Erice A., Jordan M.C. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leucocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:1996;523-528.
14. Boppana S.B., Polis M.A., Kramer A.A., Britt W.J., Koenig S. Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis. J. Infect. Dis. 171:1995;182-185.
15. Bowden R.A., Slichter S.J., Sayers J.H., Mori M., Cays M., Meyers J.D. Use of leucocyte-depleted platelets and cytomegalovirus-negative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 78:1991;246-250.
16. Bowen E.F., Wilson P., Cope A., Sabin C., Griffiths P., Davey C., Johnson H., Emery V. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS. 10:1996;1515-1520.
17. Bowen E.F., Sabin C.A., Wilson P., Griffiths P.D., Davey C.C., Johnson M.A., Emery V.C. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 11:1997;889-893.
18. Bowen E.F., Emery V.C., Wilson P.et al. CMV PCR viraemia in patients receiving ganciclovir maintenance therapy for retinitis: correlation with disease in other organs, progression of retinitis and appearance of resistance. AIDS. 12:1998;605-611.
19. Brennan D.C., Garlock K.A., Singer G.G., Schnitzler M.A., Lippmann B.J., Buller R.S., Gaudreault-Keener M., Lowell J.A., Shenoy S., Howard T.K., Storch G.A. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation. 64:1997;1843-1846.
20. Cha T.A., Tom E., Kemble G.W., Duke G.M., Mocarski E.S., Spaete R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:1996;78-83.
21. Chou S.W. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J. Infect. Dis. 155:1987;1054-1056.
22. Chou S., Erice A., Jordan M.C., Vercelotti G.M., Michels K.R., Talarico C.L., Stanat S.C., Biron K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:1995;576-583.
23. Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., Miner R.C., Drew W.L. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:1997;786-789.
24. Cochereau-Massin I., Lehoang P., Lautier-Frau M., Zazoun L., Marcel P., Robinet M., Matheron S., Katlama C., Gharakhanian S., Rozenbaum W., Ingrand D., Gentilini M. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 98:1991;1348-1352.
25. Cope A.V., Sabin C., Burroughs A., Rolles K., Griffiths P.D., Emery V.C. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176:1997;1484-1490.
26. Cope A.V., Sweny P., Sabin C., Rees L., Griffiths P.D., Emery V.C. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J. Med. Virol. 52:1997;200-205.
27. Deeks S.G., Collier A., Lalezari J., Pavia A., Rodrigue D., Drew W.L., Toole P., Jaffe H.S., Mulato A.S., Lamy P.D., Li W., Cherrington J.M., Hellmann N., Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176:1997;1517-1523.
28. Diaz-Llopis M., Espana E., Munoz G., Navea A., Chipont E., Cano J., Menezo J.L., Romero F.J. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br. J. Ophthalmol. 78:1994;120-124.
29. DiLoretto D., Epstein L.G., Lazar E.S., Britt W.J., Del Cerro M. Cytomegalovirus infection of human retinal tissue: an in vivo model. Lab. Invest. 71:1994;141-148.
30. Dockrell D.H., Prada J., Jones M.F., Patel R., Badley A.D., Harmsen W.S., Ilstrup D.M., Wiesner R.H., Krom R.A., Smith T.F., Paya C.V. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J. Infect. Dis. 176:1997;1135-1140.
31. Dodt K.K., Jacobsen P.H., Hofmann B., Meyer C., Kolmos H.J., Skinhoj P., Norrild B., Mathiesen L. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenaemia test. AIDS. 11:1997;F21-F28.
32. Drew W.L., Ives D., Lalezari J.P., Crumpacker C., Follansbee S.E., Spector S.A., Benson C.A., Friedberg D.N., Hubbard L., Stempien M.J. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med. 333:1995;615-620.
33. Drouet E., Colimon R., Michelson S., Fourcade N., Niveleau A., Ducerf C., Boibieux A., Chevallier M., Denoyel G. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J. Clin. Microbiol. 33:1995;389-394.
34. Dunn D.L., Gillingham K.J., Kramer M.A., Schmidt W.J., Erice A., Balfour H.H. Jr., Gores P.F., Gruessner R.W., Matas A.J., Payne W.D. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation. 57:1994;876-884.
35. Einsele H., Ehninger G., Steidle M., Vallbracht A., Muller M., Schmidt H., Saal J.G., Waller H.D., Muller C.A. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet. 338:1991;1170-1172.
36. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., Mackes P., Herter M., Klingebiel T., Loffler J. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
37. Erice A., Chou S., Biron K.K., Stanat S.C., Balfour H.H.J., Jordan M.C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:1989;289-293.
38. Erice A., Gil-Roda C., Perez J.L., Balfour H.H.J., Sannerud K.J., Hanson M.N., Boivin G., Chou S. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1997;1087-1092.
39. Feinberg J.E., Hurwitz S., Cooper D., Sattler F.R., MacGregor R.R., Powderly G., Holland G.N., Griffiths P.D., Pollard R.B., Youle M., Gill M.J., Holland F.J., Power M.E., Owens S., Coakley D., Fry J., Jacobson M.A. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 177:1998;48-56.
40. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:1992;663-667.
41. Fowler K.B., Stagno S., Pass R.F. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J. Infect. Dis. 168:1993;552-556.
42. Fowler K.B., McCollister F.P., Dahle A.J., Boppana S.B., Britt W.J., Pass R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J. Pediatr. 130:1997;624-630.
43. Gallant J.E., Moore R.D., Richman D.D., Keruly J., Chaisson R.E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J. Infect. Dis. 166:1992;1223-1227.
44. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., Robinson C.A. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 350:1997;1729-1733.
45. George M.J., Snydman D.R., Werner B.G., Griffith J., Falagas M.E., Dougherty N.N., Rubin R.H. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am. J. Med. 103:1997;106-113.
46. Gomez E., de Ona M., Aguado S., Tejada F., Nunez M., Portal C., Diaz C., Sanchez E., Ortega F., Alvarez-Grande J. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Nephron. 74:1996;367-372.
47. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:1993;173-178.
48. Gor D., Sabin C., Prentice H.G., Vyas N., Man S., Griffith P.D., Emery V. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acyte GVHD and CMV disease. Bone Marrow Transpl. 21:1998;579-605.
49. Gotti E., Suter F., Baruzzo S., Perani V., Moioli F., Remuzzi G. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin. Transpl. 10:1996;550-555.
50. Griffiths P.D. Prophylaxis against CMV infection in transplant patients. J. Antimicrob. Chemoth. 39:1997;299-301.
51. Griffiths P.D., Feinberg J.E., Fry J., Sabin C., Dix L., Gor D., Ansari A., Emery V.C. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. J. Infect. Dis. 177:1998;57-64.
52. Grundy J.E., Shanley J.D., Griffiths P.D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunological condition? Lancet. 2:1987;996-999.
53. Grundy J.E., Lui S.F., Super M., Berry N.J., Sweny P., Fernando C.N., Moorhead J., Griffiths P.D. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet. 2:1988;132-135.
54. Heinemann M.H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. 107:1989;1767-1772.
55. Hibberd P.L., Tolkoff-Rubin N.E., Conti D., Stuart F., Thistlethwaite J.R., Neylan J.F., Snydman D.R., Freeman R., Lorber M.I., Rubin R.H. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann. Intern. Med. 123:1995;18-26.
56. Hodge W.G., Lalonde R.G., Sampalis J., Deschenes J. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J. Infect. Dis. 174:1996;393-396.
57. Hoover D.R., Peng Y., Saah A., Semba R., Detels R.R., Rinaldo C.R.J., Phair J.P. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophtalmol. 114:1996;821-827.
58. Jacobson M.A., Causey D., Polsky B., Hardy D., Chown M., Davis R., O'Donnell J.J., Kuppermann B.D., Heinemann M.H., Holland G.N. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J. Infect. Dis. 168:1993;444-448.
59. Jacobson M.A., Zegans M., Pavan P.R., O'Donnell J.J., Sattler F., Rao N., Owens S., Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 349:1997;1443-1445.
60. Jonjic S., Pavic I., Polic B., Crnkovic I., Lucin P., Koszinowski U.H. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179:1994;1713-1717.
61. Kemble G., Duke G., Winter R., Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J. Virol. 70:1996;2044-2048.
62. Kidd I.M., Fox J.C., Pillay D., Charman H., Griffiths P.D., Emery V.C. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation. 56:1993;867-871.
63. Kirsch L.S., Arevalo J.F., Chavez D.L.P., Munguia D., De Clercq E., Freeman W.R. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency. Ophtalmology. 102:1995;533-542.
64. Knox K.K., Drobyski W.R., Carrigan D.R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant recipient. Lancet. 2:1991;1292-1293.
65. Kuhn J.E., Wendland T., Schafer P., Mohring K., Wieland U., Elgas M., Eggers H.J. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. J. Med. Virol. 44:1994;398-405.
66. Kuppermann B.D., Quinceno J.I., Flores-Aguilar M., Connor J.D., Capparelli E.U., Sherwood C.H., Freeman W.R. Intravitreal ganciclovir concentration after intravenous administration in acquired immune deficiency syndrome patients with cytomegalovirus retinitis: implications for therapy. J. Infect. Dis. 168:1993;1506-1509.
67. Manfredi R., Lazzarotto T., Spezzacatena P., Dal Monte P., Mastroianni A., Coronado O.V., Chiodo F. Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease. J. Antimicrob. Chemother. 40:1997;299-302.
68. Marenzi R., Cinque P., Ceresa D., Racca S., Lillo F., Lazzarin A. Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. Scand. J. Infect. Dis. 28:1996;347-351.
69. Martin D.F., Parks D.J., Mellow S.D., Ferris F.L., Walton R.C., Remaley N.A., Chew E.Y., Ashton P., Davis M.D., Nussenblatt R.B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch. Ophthalmol. 112:1994;1531-1539.
70. Martin D.F., Ferris F.L., Parks D.J., Walton R.C., Mellow S.D., Gibbs D., Remaley N.A., Ashton P., Davis M.D., Chan C.C., Nussenblatt R.B. Ganciclovir implant exchange. Timing, surgical procedure, and complications. Arch. Ophtalmol. 115:1997;1389-1394.
71. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., Greenberg P.D., Riddell S.R. Identification of the major late human cytomegalovirus matrix protein pp65 as a target for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:1994;103-110.
72. Merigan T.C., Renlund D.G., Keay S., Bristow M.R., Starnes V., O'Connell J.B., Resta S., Dunn D., Gamberg P., Ratkovec R.M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326:1992;1182-1186.
73. Messori A., Rampazzo R., Scroccaro G., Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transpl. 13:1994;163-167.
74. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153:1986;478-488.
75. Milburn H.J., Du B.R., Prentice H.G., Poulter L.W. Pneumonitis in bone marrow transplant recipients results from a local immune response. Clin. Exp. Immunol. 81:1990;232-237.
76. Miller W.J., McCullough J., Balfour H.H.J., Haake R.J., Ramsay N.K., Goldman R., Bowman R., Kersey J. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transpl. 7:1991;227-234.
77. The Ganciclovir Implant Study Group, Musch D.C., Martin D.F., Gordon J.F., Davis M.D., Kuppermann B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med. 337:1997;83-90.
78. Mutimer D.J., Shaw J., O'Donnell K., Elias E. Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl. Surg. 3:1997;506-512.
79. Oral Ganciclovir European and Australian Cooperative Study Group, 1995. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 9, 471-477.
80. Pari G.S., Field A.K., Smith J.A. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39:1995;1157-1161.
81. Plotkin S.A., Furukawa T., Zygraich N., Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12:1975;521-527.
82. Plotkin S.A., Smiley M.L., Friedman H.M., Starr S.E., Fleisher G.R., Wlodaver D., Dafoe D.C., Friedman A.D., Grossman R.A., Barker C.F. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet. 1:1984;528-530.
83. Plotkin S.A., Starr S.E., Friedman H.M., Gonczol E., Weibel R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159:1989;860-865.
84. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., Tustin N.B., Grossman R., Dafoe D., Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 114:1991;525-531.
85. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell D.A.J., Shope T.C., Spector S.A., Dankner W.M. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 58:1994;1176-1178.
86. Portela D., Patel R., Larson-Keller J.J., Ilstrup D.M., Wiesner R.H., Steers J.L., Krom R.A., Paya C.V. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J. Infect. Dis. 171:1995;1014-1018.
87. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N., Fernandez P., Ranada J.M., Mandelli F., Kho P., Kennedy L., Bell A.R. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 343:1994;749-753.
88. Quinnan G.V.J., Delery M., Rook A.H., Frederick W.R., Epstein J.S., Manischewitz J.F., Jackson L., Ramsey K.M., Mittal K., Plotkin S.A. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med. 101:1984;478-483.
89. Rahhal F.M., Arevalo J.F., Munguia D., Taskintuna I., Chavez D.L.P., Azen S.P., Freeman W.R. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophtalmology. 103:1996;1078-1083.
90. Rasmussen L., Morris S., Zipeto D., Fessel J., Wolitz R., Dowling A., Merigan T.C. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J. Infect. Dis. 171:1995;177-182.
91. Rasmussen L., Zipeto D., Wolitz R.A., Dowling A., Efron B., Merigan T.C. Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. J. Infect. Dis. 176:1997;1146-1155.
92. Reed J.B., Schwab I.R., Gordon J., Morse L.S. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am. J. Opthalmol. 124:1997;199-205.
93. Riddell S.R., Greenberg P.D. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:1997;181-192.
94. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 257:1992;238-241.
95. Rubin R.H. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med. 324:1991;1057-1059.
96. Rubin R.H., Tolkoff-Rubin N.E. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob. Agents Chemother. 37:1993;619-624.
97. Sarasini A.F., Baldanti M., Furione E., Percivalli F., Brerra R., Barbi M., Gerna G. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered form AIDS patients. J. Med. Virol. 47:1995;237-244.
98. Seu P., Winston D.J., Holt C.D., Kaldas F., Busuttil R.W. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation. 64:1997;1614-1617.
99. Shinkai M., Bozzette S.A., Powderly W., Frame P., Spector S.A. Utility of urine and leucocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J. Infect. Dis. 175:1997;302-308.
100. Singh N., Yu V.L., Mieles L., Wagener M.M., Miner R.C., Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann. Intern. Med. 120:1994;375-381.
101. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:1997;69-77.
102. Smith I.L., Taskintuna I., Rahhal F.M., Powell H.C., Ai E., Mueller A.J., Spector S.A., Freeman W.R. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophtalmol. 116:1998;178-185.
103. Smyth R.L., Scott J.P., Borysiewicz L.K., Sharples L.D., Stewart S., Wreghitt T.G., Gray J.J., Higenbottam T.W., Wallwork J. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J. Infect. Dis. 164:1991;1045-1050.
104. Spector S.A., McKinley G.F., Lalezari J.P., Samo T., Andruczk R., Follansbee Z., Sparti P.D., Havlir D.V., Simpson G., Buhles W., Wong R., Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med. 334:1996;1491-1497.
105. Spector S.A., Wong R., Hsia K., Pilcher M., Stempien M.J. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J. Clin. Invest. 101:1998;497-502.
106. Stagno S., Reynolds D.W., Tsiantos A., Fuccillo D.A., Long W., Alford C.A. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J. Infect. Dis. 132:1975;568-577.
107. Steinlin M.I., Nadal D., Eich G.F., Martin E., Boltshauser E.J. Late intrauterine Cytomegalovirus infection: clinical and neuroimaging findings. Pediatr. Neurol. 15:1996;249-253.
108. Studies of Ocular Complications of AIDS Research Group, 1996. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Ophtalmol. 114, 23-33.
109. Sugita K., Ando M., Makino M., Takanashi J., Fujimoto N., Niimi H. Magnetic resonance imaging of the brain in congenital rubella virus and cytomegalovirus infections. Neuroradiology. 33:1991;239-242.
110. Sullivan K.M., Kopecky K.J., Jocom J., Fisher L., Buchner C.D., Meyers J.D., Counts G.W., Bowden R.A., Peterson F.B., Whitherspoon P.P. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323:1990;705-712.
111. Tarantal A.F., Salamat M.S., Britt W.J., Luciw P.A., Hendrickx A.G., Barry P.A. Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J. Infect. Dis. 177:1998;446-450.
112. Taskintuna I., Rahhal F.M., Arevalo J.F., Munguia D., Banker A.S., De C., Freeman W.R. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophtalmology. 104:1997;1049-1057.
113. Tenney D.J., Yamanaka G., Voss S.M., Cianci C.W., Tuomari A.V., Sheaffer A.K., Alam M., Colonno R.J. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemother. 41:1997;2680-2685.
114. Tognon M.S., Turrini B., Masiero G., Scaggiante R., Cadrobbi P., Baldanti F., Gerna G., Secchi A.G. Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. Eur. J. Ophtalmol. 6:1996;179-182.
115. Tural C., Romeu J., Sirera G., Andreu D., Conejero M., Ruiz S., Jou A., Bonjoch A., Ruiz L., Arno A., Clotet B. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 177:1998;1080-1083.
116. Ussery III F.M., Gibson S.R., Conklin R.H., Piot D.F., Stool E.W., Conklin J. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 95:1988;640-648.
117. van der Meer J.T., Drew W.L., Bowden R.A., Galasso G.J., Griffiths P.D., Jabs D.A., Katlama C., Spector S.A., Whitley R.J. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral Res. 32:1996;119-140.
118. Wagner J.A., Ross H., Hunt S., Gamberg P., Valantine H., Merigan T.C., Stinson E.B. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation. 60:1995;1473-1477.
119. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.
120. Whitcup S.M., Fortin E., Nussenblatt R.B., Polis M.A., Muccioli C., Belfort R. Jr. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]. J. Am. Med. Assoc. 277:1997;1519-1520.
121. Whitley R.J., Cloud G., Gruber W., Storch G.A., Demmler G.J., Jacobs R.F., Dankner W., Spector S.A., Starr S., Pass R.F., Stagno S., Britt W.J., Alford C. Jr., Soong S., Zhou X.J., Sherrill L., FitzGerald J.M., Sommadossi J.P. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J. Infect. Dis. 175:1997;1080-1086.
122. Williamson W.D., Percy A.K., Yow M.D.et al. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics. 90:1992;862-866.
123. Winston D.J., Ho W.G., Bartoni K., Du M.C., Ebeling D.F., Buhles W.C., Champlin R.E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. 118:1993;179-184.
124. Winston D.J., Wirin D., Shaked A., Busuttil R.W. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet. 346:1995;69-74.
125. Wolf D.G., Smith I.L., Lee D.J., Freeman W.R., Flores-Aguilar M., Spector S.A. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Invest. 95:1995;257-263.
126. Xiong X., Flores C., Fuller M.D., Mendel D.B., Mulato A.S., Moon K., Chen M.S., Cherrington J.M. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir). Antiviral Res. 36:1997;131-137.
127. Zhou Y.F., Leon M.B., Waclawiw M.A., Popma J.J., Yu Z.X., Finkel T., Epstein S.E. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med. 335:1996;624-630.